D.C

STUDY OF SERUM NEURON-SPECIFIC ENOLASE AND THYMIDINE KINASE IN PATIENTS WITH LUNG CANCER

Thesis Submitted in Partial Fulfillment of the M.D. Degree in

Clinical and Chemical Pathology

By

Manal Mohamed Abd Al-Aziz

M.B., B.Ch.

M.Sc. in Clinical and Chemical Pathology

616 44424

53457

Supervised by

Prof. Dr. Hany Sobhi Rufail

Prof. of Clinical and Chemical Pathology

Ain Shams University

Prof. Dr. Mohamed Awad Tag El-Din

Prof. of Chest Disease

Ain Shams University

Prof. Dr. Nadia Ali Abdel Sattar

Prof. of Clinical and Chemical Pathology

Ain Shams University

Prof. Dr. Nafissa Amin El-Badawi

Prof. of Pathology

Ain Shams University

Dr. Ola Hamdy Demerdash

Assistant Prof. of Clinical and Chemical Pathology

Ain Shams University

Faculty of Medicine

Ain Shams University

1997

Central Library - Ain Shams University

Central Library - Ain Shams University



Central Library - Ain Shams University

ACKNOWLEDGMENT

First of all, thanks to Allah, whose help is the main factor in accomplishing this work.

I would like to express my sincere thanks and appreciation to Prof. Dr. Hany Sobhy Rufail, Prof. of Clinical and Chemical Pathology, Ain Shams University for his great support, enormous encouragement and meticulous supervision throughout the work, whatever have been said, is little to express my respect and appreciation to him.

I am indebted to Prof. Dr. Mohamed Awad Tag El-Din, Prof. of Chest Diseases, Ain Shams University, who gave me the honor of being one of my supervisors, his enormous knowledge and thorough meticulous supervision are of the main factors helped me to accomplish this work.

I am also thankful to Prof. Dr. Nadia Ali Abdel-Sattar, Professor of Clinical and Chemical Pathology, Ain Shams University, who saved no time nor effort in helping me to complete this work. Her valuable help for me was of paramount importance for the initiation and progress of this work.

Words stand short when coming to express my appreciation and thanks to Prof. Dr. Nafissa Amin El-Badawy, Prof. of Pathology, Ain Shams University, for her great help and support, unforgettable guidance, kind supervision and continuous encouragement.

ALso, I would like to thank Dr. Ola Hamdy Demerdash, Assistant Professor of Clinical and Chemical Pathology for giving me enormous help and support I will never forget her continuous support and worthy guidance.

I am also indebted to Dr. Mona Zaki, Lecturer of Clinical and Chemical Pathology, Ain Shams University, who gave me a lot of her time and knowledge and her valuable help and fruitful encouragement helped me a lot to complete this work.

Also, I would like to express my thanks and appreciation to all the staff members of Departments of Clinical Pathology, Chest, Pathology, Radiodiagnosis and Radiotherapy for giving me enormous help and support to complete this work.

Last but not least, my sincere thanks to my parents and my husband who saved no time nor effort in helping me to complete this work.

Central Library - Ain Shams University

Central Library - Ain Shams University

بسم الله الرحمن الرحيم

قالوا سبحانك لا علم لنا إلا ما علمتنا،
إنك أنت العليم الحكيم

صدق الله العظيم

سورة البقرة، الآية ٣٢

Central Library - Ain Shams University

Central Library - Ain Shams University

LIST OF ABBREVIATIONS

ACTH:	Adrenocorticotropic hormone
ADH:	Antidiuretic hormone
ALP:	Alkaline phosphatase
ALT:	Alanine aminotransferase
APUD:	Amine precursor uptake and decarboxylation
AST:	Aspartate aminotransferase
AUC:	Area under the curve
CA:	Carbohydrate antigen
CEA:	Carcinoembryonic antigen
CgA:	Chromogranin A
CLIP:	Corticotropin-like intermediate lobe peptide
CMV:	Cytomegalovirus
C.T.:	Computerized tomography
dCTP:	deoxy cytidine triphosphate
dTMP:	deoxy thymidine monophosphate
dTTP:	deoxy thymidine triphosphate
EBV:	Epstein bar virus
ED:	Extensive disease
FDU:	5-fluoro-2`-deoxyuridine
fdUMP:	5-fluoro-2`-deoxy uridine-5-monophosphate
5-FU:	5-fluorouracil
GEP:	Gastroenteropancreatic
GGT:	Gamma glutamyl transferase
GRP:	Gastrin-releasing peptide
HCG:	Human chorionic gonadotropin
HIV:	Human immunodeficiency virus
HSV:	Herpes simplex virus
IGF:	Insulin-like growth factors
K cells:	Kulchitsky cell
LD:	Limited disease
LDH:	Lactate dehydrogenase
LH:	Leutinizing hormone
LSA:	Lipid-associated sialic acid
M:	Mitosis
MGUS:	Monoclonal gamopathy of undetermined significance
MRI:	Magnetic resonance imaging

Central Library - Ain Shams University

NAD:	Nicotinamide adenine dinucleotide
NADP:	Nicotinamide adenine dinucleotide phosphate
NCAMs:	Neural cell adhesion molecules
NDL:	Non-discriminating line
NE:	Neuroendocrine
NHL:	Non-Hodgkin's lymphoma
NSCLC:	Non-small cell lung cancer
NSG:	Neurosecretory granules
OT-HNP:	Oxytoxin-human neurophysin
PCNA:	Proliferation cell nuclear antigen
PFNAB:	Percutaneous fine-needle aspiration biopsy
PNPase:	Pyrimidine nucleotide phosphorylase
POMC:	Proopiomelanocortin
PS:	Performance status
PTH:	Parathyroid hormone
RELP:	Restriction fragment length polymorphism
S:	DNA synthesis
SCC:	Squamous cell carcinoma
SCLC:	Superior vena cava
TGF:	Transferrin-like growth factors
TK:	Thymidine kinase
TPA:	Tissue polypeptide antigen
TPM:	Tissue polypeptide monoclonal antigen
TPS:	Tissue polypeptide specific antigen
TS:	Thymidylate synthetase
VIP:	Vasoactive intestinal peptide
VP-HNP:	Vasopressin-Human Neurophysin
VZV:	Varicella zoster virus
WDHA:	Watery diarrhea, hypokalemia and achlorohydria
WHO:	World Health Organization.

Central Library - Ain Shams University

LIST OF TABLES

- Table 1: Major mutagens, carcinogens and related substances in tobacco smoke
- Table 2: WHO histological classification of lung tumours
- Table 3: Extrathoracic non-metastatic manifestations
- Table 4: Influence of pretreatment performance status on survival of 5022 men with inoperable lung cancer
- Table 5: Clinical application of tumour markers
- Table 6: Tumour markers in lung cancer
- Table 7: Major neuroendocrine tumours (APUDomas)
- Table 8: Grouping of the New International Staging System (1986)
- Table (9a): Discriptive statistics of serum NSE, TK and LDH in various studied groups.
- Table (9b): Descriptive statistics of serum NSE, TK and LDH in the various subgroups of primary lung cancer patients.
- Table (10)a: Descriptive statistics of bone profile (Ca, P(i) and ALP) in various studied groups.
- Table (10b): Descriptive statistics of bone profile (Ca, P(i) and ALP) in the various subgroups of primary lung cancer patients.
- Table (11a): Descriptive statistics of serum total bilirubin, direct bilirubin, total protein and albumin in various studied groups.
- Table (11a`): Descriptive statistics of serum AST, ALT and GGT in various studied groups.
- Table (11b): Descriptive statistics of serum total bilirubin, direct bilirubin, total proteins and albumin in the various subgroups of primary lung cancer patients.
- Table (11b`): Descriptive statistics of serum AST, ALT and GGT in the various subgroups of primary lung cancer patients.
- Table (12): Statistical comparison between different studied parameters of various studied groups (SCLC, NSCLC, metastatic tumours to lung and benign lung disease groups) using Kruskal-Wallis one way test.
- Table (13): Statistical comparison between serum NSE, TK and LDH levels of patients with benign lung diseases (BLD) versus healthy controls.
- Table (14): Statistical comparison between serum NSE, TK and LDH levels of patients with SCLC versus other studied groups
- Table (15): Statistical comparison between NSE, TK and LDH levels of patients with NSCLC versus other studied groups

Central Library - Ain Shams University

- Table (16): Statistical comparison between serum NSE, TK and LDH levels of the various studied subgroups of primary lung cancer patients.
- Table (17): Statistical comparison between serum NSE, TK and LDH levels of patients with metastatic tumours to the lung (Group 3) versus healthy control and BLD group.
- Table (18): Statistical comparison between bone and liver profile parameters of patients with BLD versus healthy controls.
- Table (19): Statistical comparison between bone and liver profile parameters of patients with SCLC versus healthy control and BLD groups.
- Table (20): Statistical comparison between bone and liver profile parameters of patients with NSCLC versus healthy control and BLD groups.
- Table (21): Statistical comparison between bone and liver profile parameters of patients with metastatic tumours to the lung (group 3) versus healthy control and BLD groups.
- Table (22): Frequency of raised serum NSE, TK and LDH in the various studied groups of patients.
- Table (23a): Diagnostic reliability of serum NSE for diagnosis of SCLC at different decision levels versus BLD group.
- Table (23b): Diagnostic reliability of serum TK for diagnosis of SCLC at different decision levels versus BLD group
- Table (23c): Diagnostic reliability of serum LDH for diagnosis of SCLC at different decision levels versus BLD group
- Table (23d): Best cut-off levels and corresponding performance of serum NSE and TK, respectively for diagnosis of SCLC versus BLD group.
- Table (23e): Diagnostic reliability of the combined use of NSE and TK using the Multi-ROC rule: NSE>15 ng/ml and/or TK > variable for diagnosis of SCLC versus BLD group.
- Table (23f): Diagnostic reliability of the combined use of TK and NSE using the Multi-ROC rule: TK>6.7 U/L and/or NSE> variable for diagnosis of SCLC versus BLD group.
- Table (24a): Diagnostic reliability of serum NSE for discriminating SCLC from NSCLC
- Table (24b): Diagnostic reliability of serum TK for discriminating SCLC from NSCLC.
- Table (24c): Diagnostic reliability of serum LDH for discriminating SCLC from NSCLC.
- Table (24d): Best cut-off levels and corresponding performance of serum NSE and TK, respectively for discriminating SCLC from NSCLC.
- Table (24e): Diagnostic reliability of the combined use of NSE and TK using the Multi-ROC rule: NSE>26 ng/ml and TK > variable for discriminating SCLC from NSCLC.
- Table (24f): Diagnostic reliability of the combined use of TK and NSE using the Multi-ROC rule: TK>15 U/L and NSE > variable for discriminating SCLC from NSCLC.

Central Library - Ain Shams University

- Table (25a): Diagnostic reliability of serum NSE for diagnosis of extensive stages of SCLC at different descision levels versus limited stages.
- Table (25b): Diagnostic reliability of serum TK for diagnosis of extensive stages of SCLC at different decision levels versus limited stages.
- Table (25c): Diagnostic reliability of serum LDH for diagnosis of extensive stages of SCLC at different decision levels versus limited stages.
- Table (25d): Best cut-off levels and corresponding performance of serum NSE and TK, respectively for diagnosis of extensive stages of SCLC versus limited stages.
- Table (26a): Diagnostic reliability of serum NSE for diagnosis of NSCLC at different decision levels versus BLD group.
- Table (26b): Diagnostic reliability of TK for diagnosis of NSCLC at different decision levels versus BLD group.
- Table (26c): Diagnostic reliability of serum LDH for diagnosis of NSCLC at different decision levels versus BLD group.
- Table (26d): Best cut-off levels and corresponding performance of serum NSE and TK, respectively for diagnosis of NSCLC versus BLD group.
- Table (26e): Diagnostic reliability of combed use of NSE and TK using the Multi-ROC rule: NSE>15 ng/ml and TK>variable for diagnosis of NSCLC versus BLD group.
- Table (26f): Diagnostic reliability of combined use of TK and NSE using the Multi-ROC rule:TK>6.7 U/L and NSE > variable for diagnosis of NSCLC versus BLD group
- Table (27a): Diagnostic reliability of serum NSE for diagnosis of metastatic stages of NSCLC at different decision levels versus non-metastatic stages.
- Table (27b): Diagnostic reliability of serum TK for diagnosis of metastatic stages of NSCLC at different decision levels versus non-metastatic stages.
- Table (27c): Diagnostic reliability of serum LDH for diagnosis of metastatic stage of NSCLC at different decision levels versus non-metastatic stages.
- Table (27d): Best cut-off levels and corresponding performance of serum NSE and TK, respectively for diagnosis of metastatic stages of NSCLC versus non-metastatic stages.
- Table (27e): Diagnostic Reliability of the Combined Use of NSE and TK Using Multi-ROC Rule: NSE/22 ng/ml and TK> Variable for Diagnosis of Metastatic Stages of NSCLC Versus Non-Metastatic Stages.
- Table (27f): Diagnostic Reliability of the Combined Use of TK and NSE Using Multi-ROC Rule: TK>6.8 U/L and NSE> Variable for Diagnosis of Metastatic Stages of NSCLC Versus Non-Metastatic Stages.
- Table (28a): Diagnostic reliability of serum NSE for diagnosis of non-resectable stages of NSCLC at different levels versus resectable stages.

Central Library - Ain Shams University

- Table (28b): Diagnostic reliability of serum TK for diagnosis of non-resectable stages of NSCLC at different decision levels versus resectable stages.
- Table (28c): Diagnostic reliability of serum LDH for diagnosis of non-resectable stages of NSCLC at different decision levels versus resectable stages.
- Table (28d): Best cut-off levels and corresponding performance of serum NSE and TK, respectively for diagnosis of non-resectable stages of NSCLC versus resectable stages.
- Table (28e): Diagnostic Reliability of the Combined Use of NSE and TK Using Multi-ROC Rule:NSE>22 ng/ml and TK> Variable for Diagnosis of Non-Resectable Stages of NSCLC Versus resectable stages.
- Table (28f): Diagnostic Reliability of the Combined Use of TK and NSE Using Multi-ROC Rule: TK>8 U/L and NSE> Variable for Diagnosis of Non-Resectable Stages of NSCLC Versus Resectable Stages.
- Table (29a): Diagnostic reliability of serum NSE for diagnosis of lung cancer at different decision levels versus BLD group.
- Table (29b): Diagnostic reliability of serum TK for diagnosis of lung cancer at different decision levels versus BLD group.
- Table (29c): Diagnostic reliability of serum LDH for diagnosis of lung cancer at different decision levels versus benign chest disease group.
- Table (29d): Best cut-off levels and corresponding performance of serum NSE and TK, respectively for diagnosis of lung cancer versus BLD group.
- Table (29e): Diagnostic reliability of the combined use of NSE and TK using the Multi-ROC rule: NSE>15 ng/ml and TK>variable for diagnosis of lung cancer versus benign chest disease group.
- Table (29f): Diagnostic reliability of the combined use of TK and NSE using the Multi-ROC rule: TK>6.7 U/L and NSE>variable for diagnosis of lung cancer versus benign chest disease group.

Central Library - Ain Shams University

LIST OF FIGURES

- Fig. (1): "Y" concept describing the inter-relationship between various lung cancers.
- Fig. (2): Metabolic map of pyrimidine biosynthesis "Salvage Pathway".
- Fig. (3): Postulated model for TK synthesis during the cell cycle.
- Fig. (4): Standard curve for NSE.
- Fig. (5): Standard curve for TK.
- Fig. (6): Microscopic picture of small cell carcinoma.
- Fig. (7): Microscopic picture of large cell carcinoma.
- Fig. (8): Microscopic picture of squamous cell carcinoma.
- Fig. (9): Microscopic picture of adenocarcinoma.
- Fig. (10): Microscopic picture of metastatic adenocarcinoma.
- Fig. (11): Distribution of individual serum NSE values in various studied groups.
- Fig. (12): Distribution of individual serum TK values in various studied groups.
- Fig. (13): Distribution of individual serum LDH values in various studied groups.
- Fig. (14a): Distribution of individual serum NSE values in primary lung cancer patients according to histologic types.
- Fig. (14b): Distribution of individual serum NSE values in primary lung cancer patients according to disease extent.
- Fig. (15a): Distribution of individual serum TK values in primary lung cancer patients according to histological types.
- Fig. (15b): Distribution of individual serum TK values in primary lung cancer patients according to disease extent.
- Fig. (16a): Distribution of individual serum LDH in primary lung cancer patients according to histological types.
- Fig. (16b): Distribution of individual serum LDH in primary lung cancer patients according to disease extent.
- Fig. (17a): ROC curves of serum NSE, TK and LDH for diagnosis of SCLC versus BLD group.
- Fig. (17b): Multi-ROC curves of NSE and TK for diagnosis of SCLC versus BLD group.
- Fig. (17c): Multi-ROC curve for the rule combining the use of NSE and TK compared to ROC curves of NSE and TK for diagnosis of SCLC versus BLD group.
- Fig. (18a): ROC curves of NSE, TK and LDH for discriminating SCLC from NSCLC.
- Fig. (18b): Multi-ROC curves of NSE and TK for discriminating SCLC from NSCLC.

Central Library - Ain Shams University

- Fig. (18c): Multi-ROC curve for the rule combining the use of NSE and TK compared to the ROC curves of NSE and TK for discriminating SCLC from NSCLC.
- Fig. (19): ROC curves of serum NSE, TK and LDH for diagnosis of extensive stages of SCLC versus limited stages.
- Fig. (20a): ROC curves of serum NSE, TK and LDH for diagnosis of NSCLC versus BLD group.
- Fig. (20b): Multi-ROC curves of NSE and TK for diagnosis of NSCLC versus BLD group.
- Fig. (20c): Multi-ROC curves for the rule combining the use of NSE and TK compared to ROC curves of NSE and TK for diagnosis of SCLC versus BLD group.
- Fig. (21a): ROC curves of NSE, TK and LDH for diagnosis of metastatic stages of NSCLC versus non-metastatic stages.
- Fig. (21b): Multi-ROC curves of NSE and TK for diagnosis of metastatic stages of NSCLC versus non-metastatic stages.
- Fig. (21c): Multi-ROC curve for the rule combining the use of NSE and TK compared to ROC curves of NSE and TK for diagnosis of metastatic stages of NSCLC versus metastatic stages.
- Fig. (22a): ROC curves of serum NSE, TK and LDH for diagnosis of non-resectable stages of NSCLC versus resectable stages.
- Fig. (22b): Multi-ROC curves of NSE and TK for diagnosis of non-resectable stages of NSCLC versus resectable stages.
- Fig. (22c): Multi-ROC curve of the rule combining the use of NSE and TK compared to ROC curves of NSE and TK for diagnosis of non-resectable stages of NSCLC versus resectable stages.
- Fig. (23a): ROC curves of serum NSE, TK and LDH for diagnosis of lung cancer versus BLD group.
- Fig. (23b): Multi-ROC curves of NSE and TK for diagnosis of lung cancer versus BLD group.
- Fig. (23c): Multi-ROC curve for the rule combining the use of NSE and TK compared to ROC curves of NSE and TK for diagnosis of lung cancer versus BLD group.

Central Library - Ain Shams University